A method for expressing, as a soluble protein or an active-form mutant enzyme, an enzyme that cannot be expressed as a soluble protein or an active-form enzyme in a heterologous expression system or that is obtained in a minute amount even when an active-form enzyme is expressed, the method including a technique for selecting an effective mutation site and a mutated amino acid. A new active-form mutant enzyme is also disclosed. The method involves: specifying an insoluble protein or an inactive-form enzyme; specifying a hydrophilic amino acid in a hydrophobic domain and/or a hydrophobic amino acid in a hydrophilic domain of an -helix structure portion of the insoluble protein or the inactive-form enzyme and preparing a gene that codes for an amino acid sequence in which a substitution is made to the hydrophilic amino acid in the hydrophobic domain and/or the hydrophobic amino acid in the hydrophilic domain.

The present invention provides for a mechanism to reduce glycerol production and increase nitrogen utilization and ethanol production of recombinant microorganisms. One aspect of this invention relates to strains of S. cerevisiae with reduced glycerol productivity that get a kinetic benefit from higher nitrogen concentration without sacrificing ethanol yield. A second aspect of the invention relates tometabolic modifications resulting in altered transport and/or intracellular metabolism of nitrogen sources present in corn mash.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The present disclosure relates to a microorganism with L-isoleucine-producing ability, into which a foreign gene encoding glutamate dehydrogenase is introduced, a method of producing L-isoleucine using the microorganism, and a composition for producing L-isoleucine, the composition including the microorganism.

Methods for use of a multi-arm polyethylene glycol (PEG) modifier in modification of asparaginase. The described multi-arm PEG modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity.

The present invention refers to a modified glutamate dehydrogenase (GluDH). In particular the modified GluDH of the present invention has an increased activity for catalyzing the reaction of 4-(hydroxymethylphosphinyl)-2-oxobutanoic acid (PPO) and an amino donor to generate L-glufosinate and/or an improved dynamic property. The present invention also refers to the polynucleotide encoding the modified GluDH of the present invention, the vector and host cell for expressing the modified GluDH of the present invention and the method of producing L-glufosinate with the modified GluDH and host cell of the present invention.

Healthcare costs are a significant worldwide, with many patients being denied medications because of their high prices. One approach to addressing this problem involves the biosynthesis of chiral drug intermediates, an environmentally friendly solution that can be used to generate pharmaceuticals at much lower costs than conventional techniques. In this context, embodiments of the invention comprise methods and materials designed to allow microorganisms to biosynthesize the nonnatural amino acid L-homoalanine. As is known in the art, L-homoalanine is a chiral precursor of a variety of pharmaceutically valuable compounds including the anticonvulsant medications levetiracetam (sold under the trade name Keppra) and brivaracetam, as well as ethambutol, a bacteriostatic antimycobacterial drug used to treat tuberculosis. Consequently, embodiments of the invention can be used in low cost, environmentally friendly processes to generate these and other valuable compounds.

A microorganism is transformed to be capable of producing guanidinoacetic acid (GAA) having an inactivated amino acid exporter. The microorganism is used in a method for the fermentative production of GAA. Moreover, creatine is produced by a method of fermentative production.

Provided are a theanine-producing strain and use thereof in tea fermentation production. A corynebacterium glutamicum is proposed, which includes an alanine decarboxylase CsAlaDC mutant. The theanine-producing strain is obtained by taking the corynebacterium glutamicum as a starting strain, knocking out in sequence an -ketoglutarate dehydrogenase E1 subunit gene odhA, a glutamate external transporter gene Ncg11221 and a lactate dehydrogenase gene ldh; and/or expressesing a citrate synthase gene gltA, a pyruvate kinase gene pyk and a glutamate dehydrogenase gene gdh; and/or overexpressing an alanine dehydrogenase alaA and integrating a -glutamine synthetase GMAS into a cg1960 pseudogene locus of the corynebacterium glutamicum.

Provided are a theanine-producing strain and use thereof in tea fermentation production. A Corynebacterium glutamicum is proposed, which includes an alanine decarboxylase CsAlaDC mutant. The theanine-producing strain is obtained by taking the Corynebacterium glutamicum as a starting strain, knocking out in sequence an -ketoglutarate dehydrogenase E1 subunit gene odhA, a glutamate external transporter gene Ncg11221 and a lactate dehydrogenase gene ldh; and/or expressing a citrate synthase gene gltA, a pyruvate kinase gene pyk and a glutamate dehydrogenase gene gdh; and/or overexpressing an alanine dehydrogenase alaA and integrating a -glutamine synthetase GMAS into a cg1960 pseudogene locus of the Corynebacterium glutamicum.